Tysabri and Rebetol drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tysabri (natalizumab) and Rebetol (ribavirin). Common drug interactions include haemoglobin decreased among females and white blood cell count decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Tysabri and Rebetol. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Tysabri?

Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. eHealthMe is studying from 221,369 Tysabri users. Check the latest studies of Tysabri.

What is Rebetol?

Rebetol has active ingredients of ribavirin. eHealthMe is studying from 25,932 Rebetol users. Check the latest studies of Rebetol.



On Jul, 10, 2026

16 people who take Tysabri and Rebetol together, and have interactions are studied.

Tysabri and Rebetol drug interactions.

What are the common drug interactions of Tysabri and Rebetol, by gender? *:

female:

  1. Haemoglobin decreased
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Renal disorder (kidney disease)
  4. White blood cell count decreased
  5. Cystitis (inflammation of the wall of the bladder)
  6. Diarrhoea
  7. Dizziness
  8. Nausea (feeling of having an urge to vomit)
  9. Renal impairment (severely reduced kidney function)
  10. Vomiting

male:

  1. White blood cell count decreased
  2. Fatigue (feeling of tiredness)
  3. Rash
  4. Anxiety
  5. Arthralgia (joint pain)
  6. Asthenia (weakness)
  7. Attention deficit/hyperactivity disorder
  8. Blindness
  9. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  10. Drug eruption (adverse drug reaction of the skin)

What are the common drug interactions of Tysabri and Rebetol, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Haemoglobin decreased
  2. Nausea (feeling of having an urge to vomit)
  3. Renal disorder (kidney disease)
  4. Cystitis (inflammation of the wall of the bladder)
  5. Diarrhoea
  6. Pharyngitis (inflammation of the pharynx, causing a sore throat)
  7. Stomatitis (inflammation of mucous membrane of mouth)
  8. Vertigo
  9. Abortion spontaneous (naturally occurring miscarriage)
  10. Mania (a state of abnormally elevated or irritable mood)

40-49:

  1. White blood cell count decreased
  2. Decreased appetite
  3. Procedural pain
  4. Shoulder operation
  5. Rash
  6. Diarrhoea
  7. Nephrolithiasis (calculi in the kidneys)

50-59:

  1. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  2. Malaise (a feeling of general discomfort or uneasiness)
  3. Dizziness
  4. Renal impairment (severely reduced kidney function)
  5. Vomiting
  6. Balance disorder
  7. Haemoglobin decreased
  8. Memory impairment
  9. Nervousness
  10. White blood cell count decreased

60+:

  1. Insomnia (sleeplessness)
  2. Fatigue (feeling of tiredness)
  3. Asthenia (weakness)
  4. Basedow's disease (autoimmune disease where the thyroid is overactive, producing an excessive amount of thyroid hormones)
  5. Constipation
  6. Cystitis (inflammation of the wall of the bladder)
  7. Decreased appetite
  8. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  9. Diarrhoea
  10. Disease recurrence

What are the existing conditions these people have? *

  1. Hepatitis C: 9 people, 56.25%
  2. Rashes (redness): 2 people, 12.50%
  3. High Blood Pressure: 2 people, 12.50%
  4. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 1 person, 6.25%
  5. Nausea (feeling of having an urge to vomit): 1 person, 6.25%
  6. Migraine (headache): 1 person, 6.25%
  7. Meniere's Disease (a disorder of the inner ear that can affect hearing and balance to a varying degree): 1 person, 6.25%
  8. Malaise (a feeling of general discomfort or uneasiness): 1 person, 6.25%
  9. Iron Deficiency Anaemia: 1 person, 6.25%
  10. Hyperuricaemia (level of uric acid in the blood that is abnormally high): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Tysabri and Rebetol?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tysabri and Rebetol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tysabri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Rebetol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tysabri and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Rebetol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on natalizumab and ribavirin (the active ingredients of Tysabri and Rebetol, respectively), and Tysabri and Rebetol (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: